keyword
MENU ▼
Read by QxMD icon Read
search

Alendronate

keyword
https://www.readbyqxmd.com/read/28228784/atypical-periprosthetic-acetabular-fracture-in-long-term-alendronate-therapy
#1
Giuseppe Marongiu, Antonio Capone
Bisphosphonates have been commonly used in the treatment of osteoporosis, demonstrating its efficacy in fracture risk reduction. However, even if are generally safe and well tolerated, concerns have emerged about atypical fractures related to its prolonged use. Although atypical femoral fracture are more common, case reports demonstrated that even other skeletal areas can be involved by unusual pattern of fracture. We report a atypical acetabular periprosthetic fracture in a 83-year-old female patient after prolonged alendronate treatment for osteoporosis and isolated acetabular revision surgery...
September 2016: Clinical Cases in Mineral and Bone Metabolism
https://www.readbyqxmd.com/read/28228782/safety-and-effectiveness-of-teriparatide-vs-alendronate-in-postmenopausal-osteoporosis-a-prospective-non-randomized-clinical-study
#2
Gianfilippo Caggiari, Paolo Tranquilli Leali, Giulia Raffaella Mosele, Leonardo Puddu, Francesca Badessi, Carlo Doria
In this work we study the safety and effectiveness of teriparatide and alendronate in patients with postmenopausal osteoporosis at high risk of fracture; it was a double-blinded and it was done by examining the comparisons between teriparatide 20 μg/day and alendronate 10 mg/day. Safety and effectiveness analyses were based on data from 355 woman with a mean age of 68 years. Two groups (A and B) with T-score ≤-2.5 at bone mineral density were analyzed and 3 or more vertebral fractures on radiograph. Group A: was treated with teriparatide 20 μg/day and composed from 182 women, in post-menopausal age, without a history of cancer...
September 2016: Clinical Cases in Mineral and Bone Metabolism
https://www.readbyqxmd.com/read/28228781/denosumab-is-really-effective-in-the-treatment-of-osteoporosis-secondary-to-hypogonadism-in-prostate-carcinoma-patients-a-prospective-randomized-multicenter-international-study
#3
Carlo Doria, Paolo Tranquilli Leali, Federico Solla, Gianluca Maestretti, Massimo Balsano, Robero Mario Scarpa
INTRODUCTION: Osteoporosis is a complication of androgen deprivation therapy (ADT) in men with prostate carcinoma. The best defense against osteoporosis in prostate cancer is to identify patients with a high risk for fracture during the first clinical visit, select an effective anti-osteoporosis agent, and advise the patient to change his lifestyle and diet to prevent further bone loss. New agents include denosumab, a human monoclonal antibody that inhibits the RANK ligand (RANKL). RANKL promotes the formation, activity, and survival of osteoclasts and, thus, supports the breakdown of bone...
September 2016: Clinical Cases in Mineral and Bone Metabolism
https://www.readbyqxmd.com/read/28220293/effects-of-bisphosphonates-on-osteogenesis-and-osteoclastogenesis-signaling-during-the-endochondral-ossification-of-growing-rats
#4
Eloiza Rezende, Vivian Bradaschia-Correa, Fabio Siviero, Lucas M B Ambrosio, Victor E Arana-Chavez
Osteoclasts and chondroclasts are necessary, during endochondral ossification, for the resorption of primary bone and calcified cartilage septa, respectively. The bisphosphonates inhibit mineralized tissue resorption by various mechanisms according to the different types of this drug, which can affect bone remodeling during skeletal growth. The objective of the present study is to analyze the way that alendronate (ALN) and etidronate (ETN) can affect osteoclastogenesis and bone formation during endochondral ossification of the long bones of growing rats...
February 20, 2017: Cell and Tissue Research
https://www.readbyqxmd.com/read/28214864/a-comparative-study-of-intravenous-injection-form-and-oral-jelly-form-of-alendronate-sodium-hydrate-for-bone-mineral-disorder-after-gastrectomy
#5
Chikara Kunisaki, Yusaku Tanaka, Takashi Kosaka, Hiroshi Miyamoto, Sho Sato, Hideaki Suematsu, Norio Yukawa, Kei Sato, Yusuke Izumisawa, Hirotoshi Akiyama, Masataka Taguri, Takeharu Yamanaka, Itaru Endo
BACKGROUND/AIMS: Osteoporosis is found to have high prevalence after gastrectomy and therefore, it is important to prevent this condition by means of effective medication, such as alendronate sodium hydrate. METHODS: A total number of 48 gastric cancer patients diagnosed with osteoporosis after R0 gastrectomy was registered in this study between December 2013 and August 2014. Twenty-three patients received intravenous (i.v.) alendronate sodium hydrate and 25 patients received the drug in an oral jelly form...
February 18, 2017: Digestion
https://www.readbyqxmd.com/read/28210968/study-on-critical-sized-ultra-high-molecular-weight-polyethylene-wear-particles-loaded-with-alendronate-sodium-in-vitro-release-and-cell-response
#6
Yumei Liu, Feng Shi, Kemeng Gong, Yang Liu, Wei Zhi, Jie Weng, Shuxin Qu
The aim of this study was to investigate the in vitro release and the effect of RAW 264.7 macrophages of critical-sized wear particles of ultra-high molecular weight polyethylene (UHMWPE) loaded with alendronate sodium (ALN), one of the most effective drugs to treat osteoporosis in clinic. The critical-sized UHMWPE-ALN 0.5 wt.% wear particles were prepared by vacuum gradient filtration combined with Pluronic F-68. In vitro release of ALN from critical-sized UHMWPE-ALN wear particles was investigated in phosphate buffered saline (PBS) at 37 °C with a shaker...
April 2017: Journal of Materials Science. Materials in Medicine
https://www.readbyqxmd.com/read/28210776/cost-effectiveness-of-denosumab-versus-oral-alendronate-for-elderly-osteoporotic-women-in-japan
#7
T Mori, C J Crandall, D A Ganz
: We constructed a Markov microsimulation model among hypothetical cohorts of community-dwelling elderly osteoporotic Japanese women without prior hip or vertebral fractures over a lifetime horizon. Compared with weekly oral alendronate for 5 years, denosumab every 6 months for 5 years is cost-saving or cost-effective at a conventionally accepted threshold. INTRODUCTION: The objective of the study was to examine the cost-effectiveness of subcutaneous denosumab every 6 months for 5 years compared with weekly oral alendronate for 5 years in Japan...
February 17, 2017: Osteoporosis International
https://www.readbyqxmd.com/read/28210623/in-vitro-and-in-vivo-evaluation-of-commercially-available-fibrin-gel-as-a-carrier-of-alendronate-for-bone-tissue-engineering
#8
Beom Su Kim, Feride Shkembi, Jun Lee
Alendronate (ALN) is a bisphosphonate drug that is widely used for the treatment of osteoporosis. Furthermore, local delivery of ALN has the potential to improve the bone regeneration. This study was designed to investigate an ALN-containing fibrin (fibrin/ALN) gel and evaluate the effect of this gel on both in vitro cellular behavior using human mesenchymal stem cells (hMSCs) and in vivo bone regenerative capacity. Fibrin hydrogels were fabricated using various ALN concentrations (10(-7)-10(-4 )M) with fibrin glue and the morphology, mechanical properties, and ALN release kinetics were characterized...
2017: BioMed Research International
https://www.readbyqxmd.com/read/28204953/pharmacokinetics-of-coadministration-of-levothyroxine-sodium-and-alendronate-sodium-new-effervescent-formulation
#9
H G Bone, M A Walter, M E Hurley, S Epstein
: No clinically important pharmacokinetic interference of alendronate occurred between a new effervescent formulation of alendronate and levothyroxine when coadministered. The combination does not materially affect levothyroxine absorption. INTRODUCTION: Concurrent treatment of osteoporosis with alendronate (Aln) and hypothyroidism with levothyroxine (LT4) may be problematic because both drugs are to be taken separately after fasting overnight. The primary objective was to assess pharmacokinetic interactions between a new effervescent formulation of Aln (Aln-NEF) and LT4...
February 16, 2017: Osteoporosis International
https://www.readbyqxmd.com/read/28199089/technetium-i-complexes-of-bathophenanthrolinedisulfonic-acid
#10
Abdolreza Yazdani, Nancy Janzen, Shannon Czorny, John F Valliant
Bathophenanthrolinedisulfonate (BPS) complexes of technetium(I) of the type [Tc(CO)3(BPS)(L)](n) (L = imidazole derivatives) were synthesized and evaluated both in vitro and in vivo. [(99m)Tc(CO)3(BPS)(MeIm)](-) (MeIm = 1-methyl-1H-imidazole) was prepared in near-quantitative yield using a convenient two-step, one-pot labeling procedure. A targeted analogue capable of binding regions of calcium turnover associated with bone metabolism was also prepared. Here, a bisphosphonate was linked to the metal through an imidazole ligand to give [(99m)Tc(CO)3(BPS)(ImAln)](2-) (ImAln = an imidazole-alendronate ligand) in high yield...
February 15, 2017: Inorganic Chemistry
https://www.readbyqxmd.com/read/28198975/short-term-sodium-alendronate-administration-improves-the-peri-implant-bone-quality-in-osteoporotic-animals
#11
Danila de Oliveira, Jaqueline Suemi Hassumi, Pedro Henrique da Silva Gomes-Ferreira, Tárik Ocon Braga Polo, Gabriel Ramalho Ferreira, Leonardo Perez Faverani, Roberta Okamoto
Objective: The aim of this study was to evaluate the bone repair process at the bone/implant interface of osteoporotic rats treated with sodium alendronate through the analysis of microtomography, real time polymerase chain reactions and immunohistochemistry (RUNX2 protein, bone sialoprotein (BSP), alkaline phosphatase, osteopontin and osteocalcin). Material and Methods: A total of 42 rats were used and divided in to the following experimental groups: CTL: control group (rats submitted to fictitious surgery and fed with a balanced diet), OST: osteoporosis group (rats submitted to a bilateral ovariectomy and fed with a low calcium diet) and ALE: alendronate group (rats submitted to a bilateral ovariectomy, fed with a low calcium diet and treated with sodium alendronate)...
January 2017: Journal of Applied Oral Science: Revista FOB
https://www.readbyqxmd.com/read/28181177/outcomes-associated-with-generic-drugs-approved-using-product-specific-determinations-of-therapeutic-equivalence
#12
Joshua J Gagne, Jennifer M Polinski, Wenlei Jiang, Sarah K Dutcher, Jing Xie, Joyce Lii, Lisa A Fulchino, Aaron S Kesselheim
OBJECTIVE: We sought to examine rates of clinical outcomes among patients before and after market introduction of generic versions of five drugs approved using product-specific equivalence determinations. METHODS: We used data from a large national insurer to identify patients who initiated a study (acarbose tablets, salmon calcitonin nasal spray, enoxaparin injection, vancomycin capsules, venlafaxine extended-release tablets) or control drug (nateglinide, glimepiride, alendronate, fondaparinux, metronidazole, sertraline, paroxetine) in each calendar month between 2003 and 2012 and to determine rates of claims-based proxies for lack of effectiveness outcomes following initiation...
February 8, 2017: Drugs
https://www.readbyqxmd.com/read/28164049/a-case-report-of-bisphosphonate-induced-bilateral-osteoporotic-subtrochanteric-fracture-femurii-review-of-literature
#13
Rajendra Uppin, Srinath Gupta, Shivank Prakash
INTRODUCTION: Osteoporosis is a significant health-care problem characterized by excessive skeletal fragility, susceptibility to low-trauma fractures in men as well as women. Any abnormality of the bone that reduces the strength of the bone predisposes it to mechanical failure during normal activity or with minimum trauma. The mechanical failure manifests itself as a fracture, and this fracture must be recognized as a pathological fracture if the patient is to be treated properly. Osteoporosis is one of the leading causes of such pathological fractures and accounts for 1...
September 2016: Journal of Orthopaedic Case Reports
https://www.readbyqxmd.com/read/28160873/eighteen-months-of-treatment-with-subcutaneous-abaloparatide-followed-by-6-months-of-treatment-with-alendronate-in-postmenopausal-women-with-osteoporosis-results-of-the-activextend-trial
#14
Felicia Cosman, Paul D Miller, Gregory C Williams, Gary Hattersley, Ming-Yi Hu, Ivo Valter, Lorraine A Fitzpatrick, Bente Juel Riis, Claus Christiansen, John P Bilezikian, Dennis Black
OBJECTIVE: To assess the efficacy and safety of 18 months of subcutaneous abaloparatide (ABL-SC) or placebo (PBO) followed by 6 months of alendronate (ALN) (preplanned interim analysis). PATIENTS AND METHODS: ACTIVExtend, an extension of ACTIVE, enrolled patients who completed 18 months of ABL-SC or PBO in ACTIVE to receive up to 24 additional months of open-label ALN; there was 1 month between the studies to re-consent patients. RESULTS: Of 1243 eligible ACTIVE patients, 1139 (92%) were enrolled in ACTIVExtend beginning November 20, 2012...
February 2017: Mayo Clinic Proceedings
https://www.readbyqxmd.com/read/28152215/comparison-of-generic-to-brand-switchback-rates-between-generic-and-authorized-generic-drugs
#15
Richard A Hansen, Jingjing Qian, Richard Berg, James Linneman, Enrique Seoane-Vazquez, Sarah K Dutcher, Saeid Raofi, C David Page, Peggy Peissig
STUDY OBJECTIVE: Generic drugs contain identical active ingredients as their corresponding brand drugs and are pharmaceutically equivalent and bioequivalent, whereas authorized generic drugs contain both identical active and inactive ingredients as their corresponding brand drugs but are marketed as generics. The objective of this study was to compare generic-to-brand switchback rates between generic and authorized generic drugs. DESIGN: Retrospective cohort study...
February 2, 2017: Pharmacotherapy
https://www.readbyqxmd.com/read/28140360/assembling-of-electrospun-meshes-into-three-dimensional-porous-scaffolds-for-bone-repair
#16
Juqing Song, Guanglin Zhu, Lin Wang, Geng An, Xuetao Shi, Yingjun Wang
Technical limitations of traditional electrospinning make it hard to produce three-dimensional (3D) scaffolds with hierarchical pore structures. Here, porous polycaprolactone (PCL) nanofiber meshes with different nano-hydroxyapatite (nHA) concentrations were prepared by electrospinning with stainless steel mesh as the collector, and 3D porous nanofiber scaffolds were fabricated via layer-by-layer assembly with a special binder (18% PCL/DCM solution). The single layer nanofiber mesh possessed very regular morphology with a hollow structure, and the nHA was not only embedded in the nanofiber but also exposed on the surfaces of the fiber, resulting in the improved surface chemical properties...
February 14, 2017: Biofabrication
https://www.readbyqxmd.com/read/28134449/engineered-multifunctional-nanomedicine-for-simultaneous-stereotactic-chemotherapy-and-inhibited-osteolysis-in-an-orthotopic-model-of-bone-metastasis
#17
Chunyan Li, Yejun Zhang, Guangcun Chen, Feng Hu, Kui Zhao, Qiangbin Wang
A novel multifunctional Ag2 S quantum dot (QD)-based nanomedicine of alendronate (Ald)/doxorubicin (DOX)@Ag2 S is developed for highly effective bone tumor therapy in an orthotopic model. The bone-targeting and osteolysis inhibition of Ald and the chemotherapeutic effect of DOX on the bone tumor are in situ visualized by Ag2 S QDs with emission in the second near-infrared window.
January 30, 2017: Advanced Materials
https://www.readbyqxmd.com/read/28134399/-nephrolithiasis-associated-with-normocalcemic-or-hypercalcemic-primary-hyperparathyroidism-focus-on-calciomimetics
#18
Simone Brardi, Roberto Ponchietti, Ennio Duranti
Primary hyperparathyroidism (PHPT) is a disease involving a broad range of alterations of calcium homeostasis, sustained by parathyroid hormone (PTH) levels that are clearly abnormal. The anomalies directly associated with hyperparathyroidism are nephrolithiasis and fibrocystic bone disease. Since PHPT resolves when abnormal parathyroid tissue is removed, surgery is clearly the only definitive approach to this type of hyperparathyroidism. However there are large subgroups of patients for whom medical therapy should be considered instead of surgery...
November 2016: Giornale Italiano di Nefrologia: Organo Ufficiale Della Società Italiana di Nefrologia
https://www.readbyqxmd.com/read/28127706/new-insights-into-the-tonifying-kidney-yin-herbs-and-formulas-for-the-treatment-of-osteoporosis
#19
REVIEW
Jian-Bo He, Mei-Hui Chen, Ding-Kun Lin
Osteoporosis is characterized by an increasing osseous fragility and fracture resulting from the low mass and deteriorated microarchitecture in the bone tissue. The hormone replacement therapy and alendronate were frequently used to treat osteoporosis as the primary therapeutic strategy, but their adverse effects have severely limited their extensive clinical application, therefore, it is urgent to develop alternative or complementary therapeutic agents for anti-osteoporosis. Interestingly, with more people focusing on the complementary and alternative medicine, traditional Chinese herbs and formulas are being gradually recognized as safe and effective agents in the treatment of osteoporosis...
December 2017: Archives of Osteoporosis
https://www.readbyqxmd.com/read/28123122/-evidence-for-positive-effects-of-long-term-bisphosphonate-administration
#20
Hiroshi Hagino
Long-term treatment studies on the use of bisphosphonate(BP)for more than 5 years have been reported for alendronate, risedronate, and zoledronic acid. Bone mineral density(BMD)increases over the long term;however, a large increase has been observed over a 2 to 3 year period after initiation of BP treatment followed by gradual BMD increase and achieving a state of stability. After an initial reduction, the levels of bone remodeling markers remained stable within the premenopausal range during long-term BP treatment...
2017: Clinical Calcium
keyword
keyword
27344
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"